Aggressive statin therapy for acute coronary syndromes
| Autor: | Tze Vun Liew, Kausik K. Ray, BChir |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Secondary prevention
Clinical Trials as Topic medicine.medical_specialty biology business.industry Myocardial Infarction Coronary heart disease Treatment Outcome Internal medicine HMG-CoA reductase medicine Cardiology biology.protein Humans Angina Unstable Statin therapy Hydroxymethylglutaryl-CoA Reductase Inhibitors Cardiology and Cardiovascular Medicine Intensive care medicine business Medical therapy Very high risk Disease burden |
| Zdroj: | Current Cardiology Reports. 9:298-302 |
| ISSN: | 1534-3170 1523-3782 |
| DOI: | 10.1007/bf02938378 |
| Popis: | Acute coronary syndromes (ACS) account for an enormous disease burden, especially in the Western world. Patients suffering acute coronary events are now understood to carry a very high risk of further coronary events and although improvements in conventional medical therapy over the past two decades have significantly reduced the risk, it remains high. Therapy with HMG CoA reductase inhibitors (statins) have now been well established for the primary and secondary prevention of stable coronary heart disease, but recently a substantial body of evidence has proven their efficacy in the treatment of ACS. This article examines this emerging evidence for the use of statins in ACS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink